Model DetailsLeukocyte - Lymphocyte - T-lymphocyte lymphoma - lymphoblastic
Model Name |
Leukocyte - Lymphocyte - T-lymphocyte lymphoma - lymphoblastic | Strain |
CD-1 |
Tumor Inducing Agent(s) |
Chemical/Drug : 3'-azido-3'-deoxythymidine (AZT) |
Tumor Synonyms |
hematopoietic neoplasm • hematopoietic tumor • LL, lymphoblastic lymphoma • lymphoblastic lymphoma (T-cell origin) • lymphoblastic lymphoma |
Strain Synonyms |
outbred CD-1 • Swiss CD-1® • CD1 nontransgenic • Charles River CD-1 • Swiss CD-1 • Crl:CD-1®(ICR) • outbred CD1 • (Swiss) CD-1 • CD1 • Crl:CD-1(ICR)BR • ICR Crj:CD-1 • random-bred Crl:CD-1(ICR)BR • CD-1 outbred • Crl:CD-1 (ICR) BR • Crj:CD-1(ICR) • ICR(CD-1) • Crl: CD-1 (ICR) BR • ICR |
| Organ Affected | Sex | Frequency | Age Of Detection | Additional Information Expand all Collapse all | Reference |
|---|---|---|---|---|---|
| Leukocyte - Lymphocyte - T-lymphocyte | Female |
9.1% (2 of 22 mice) |
1 year |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Female |
0% (0 of 32 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Female |
3.7% (2 of 54 mice) |
1-2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Female |
0% (0 of 24 mice) |
1 year |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Female |
0% (0 of 27 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Female |
0% (0 of 51 mice) |
1-2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Male |
0% (0 of 23 mice) |
1 year |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Male |
3.6% (1 of 28 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Male |
2.0% (1 of 51 mice) |
1-2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Male |
0% (0 of 26 mice) |
1 year |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Male |
7.1% (2 of 28 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Male |
3.7% (2 of 54 mice) |
1-2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Female |
0% (0 of 14 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Female |
25% (2 of 8 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Female |
0% (0 of 16 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Female |
0% (0 of 10 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Male |
5.3% (1 of 19 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Male |
7.1% (1 of 14 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Male |
6.7% (1 of 15 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Leukocyte - Lymphocyte - T-lymphocyte | Male |
0% (0 of 14 mice) |
2 years |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |